HopeStage
Back to all studies
CompletedNCT04979910

Ixekizumab study for people with treatment-resistant depression

About this titleRead the official source — NCT04979910
Medication studyAges 18–70United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 27, 2021
Recruitment status
Completed
Enrollment listed in the registry
7
Sponsor
Icahn School of Medicine at Mount Sinai
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 70 Years
Official registry ID
NCT04979910
Official title
Show the full official title

An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Icahn School of Medicine at Mount Sinai, a university.

Did this study involve medication?

Yes. The study involved medication, including Ixekizumab.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies